Merck & Co. reported positive results from the Phase III KEYNOTE-689 trial of KEYTRUDA for head and neck cancer treatment. The trial met its primary endpoint of event-free survival, with significant improvements in key secondary endpoints like major pathological response. The safety profile was consistent with previous studies.